反应详情

A mixture of N1-[5-chloro-2-(1H-tetraazol-1-yl)benzyl]-N2-cyclopropylglycinamide (50 mg, 0.16 mmol), N-(tert-butoxycarbonyl)-4-methyl-D-leucine (42 mg, 0.17 mmol), EDC (49 mg, 0.26 mmol) and HOAt (16 mg, 0.12 mmol) in DMF (1.4 mL) was stirred for 16 h at room temperature. The title compound was isolated by reverse phase HPLC as a white foam and was carried on directly to deprotection. LCMS (M+H): 534.1.